Fibrinogen and the risk of thrombosis
P De Moerloose, F Boehlen… - … in thrombosis and …, 2010 - thieme-connect.com
Fibrinogen contributes to thrombosis risk in different ways. Indeed, various mutations in the
fibrinogen genes predispose to thrombosis. At the same time, high levels of fibrinogen are …
fibrinogen genes predispose to thrombosis. At the same time, high levels of fibrinogen are …
Intermittent claudication: an overview
AV Meru, S Mittra, B Thyagarajan, A Chugh - Atherosclerosis, 2006 - Elsevier
Intermittent claudication (IC) is defined by leg muscle pain, cramping and fatigue brought on
by ambulation/exercise; relieved on rest; and caused by inadequate blood supply and is the …
by ambulation/exercise; relieved on rest; and caused by inadequate blood supply and is the …
Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension
L Taraseviciene-Stewart… - … of Physiology-Lung …, 2006 - journals.physiology.org
Severe pulmonary hypertension (SPH) is characterized by precapillary arteriolar lumen
obliteration, dramatic right ventricular hypertrophy, and pericardial effusion. Our recently …
obliteration, dramatic right ventricular hypertrophy, and pericardial effusion. Our recently …
Biomarkers of peripheral arterial disease
Atherosclerotic arterial occlusive disease affecting the lower extremities is also known as
peripheral artery disease (PAD). This disorder affects 8 to 12 million individuals in the US …
peripheral artery disease (PAD). This disorder affects 8 to 12 million individuals in the US …
Does diabetes mellitus play a role in restenosis and patency rates following lower extremity peripheral arterial revascularization? A critical overview
KI Paraskevas, DM Baker, A Pompella… - Annals of vascular …, 2008 - Elsevier
Patients with diabetes mellitus (DM) are at increased risk of developing lower extremity
peripheral arterial disease (PAD). The effect of DM on restenosis and patency rates in …
peripheral arterial disease (PAD). The effect of DM on restenosis and patency rates in …
[HTML][HTML] Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?
KI Paraskevas, CD Liapis, G Hamilton… - European journal of …, 2006 - Elsevier
AIMS: To determine whether statins can reduce perioperative morbidity and mortality in
patients undergoing non-cardiac vascular surgery. METHODS: A search using Pubmed was …
patients undergoing non-cardiac vascular surgery. METHODS: A search using Pubmed was …
Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease
SG Ma, CL Wei, B Hong, WN Yu - Clinics, 2011 - SciELO Brasil
OBJECTIVE: To determine whether there is an association between serum ischemia-
modified albumin and the risk factor profile in type 2 diabetic patients with peripheral arterial …
modified albumin and the risk factor profile in type 2 diabetic patients with peripheral arterial …
The role of fibrinogen and fibrinolysis in peripheral arterial disease
KI Paraskevas, DM Baker, GE Vrentzos… - Thrombosis research, 2008 - Elsevier
Peripheral arterial disease (PAD) is associated with high rates of cerebrovascular and
cardiovascular events; PAD is a marker of systemic atherosclerosis. As a result, standard …
cardiovascular events; PAD is a marker of systemic atherosclerosis. As a result, standard …
Emerging indications for statins: a pluripotent family of agents with several potential applications
KI Paraskevas, AA Tzovaras, DD Briana… - Current …, 2007 - ingentaconnect.com
Statins are pluripotent agents exhibiting multiple non-lipid-lowering actions. Besides their
established role in the management of hypercholesterolemia, statins may also have …
established role in the management of hypercholesterolemia, statins may also have …
The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel
DP Mikhailidis, AS Wierzbicki… - … medical research and …, 2005 - Taylor & Francis
There is no doubt that lowering serum cholesterol levels reduces the risk of major coronary
events. This evidence has led treatment guidelines to set progressively lower targets for low …
events. This evidence has led treatment guidelines to set progressively lower targets for low …